Diletta Fontana

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 27

Top Topics

Tyrosine Kinase

Top Venues

Annals of hematology

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Diletta Fontana, Federica Malighetti, Matteo Villa, Alfonso Zambon, Carlo B Gambacorti-Passerini, Luca Mologni
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. Leukemia 38 (8) (2024)
Matteo Villa, Federica Malighetti, Elisa Sala, Geeta G Sharma, Giulia Arosio, Maria Gemelli, Chiara Manfroni, Diletta Fontana, Nicoletta Cordani, Raffaella Meneveri, Alfonso Zambon, Rocco Piazza, Fabio Pagni, Diego Luigi Cortinovis, Luca Mologni
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ precision oncology 8 (1) (2024)
Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, Rocco Piazza, Carlo Gambacorti-Passerini
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape. Annals of hematology 103 (5) (2024)
Diletta Fontana, Federica Malighetti, Matteo Villa, Alfonso Zambon, Carlo B Gambacorti-Passerini, Luca Mologni
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. Leukemia 38 (8) (2024)
Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, Rocco Piazza, Carlo Gambacorti-Passerini
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape. Annals of hematology 103 (5) (2024)
Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, Rocco Piazza, Carlo Gambacorti-Passerini
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape. Annals of hematology 103 (5) (2024)
Ilaria Crespiatico, Mattia Zaghi, Cristina Mastini, Deborah D'Aliberti, Mario Mauri, Carl Mirko Mercado, Diletta Fontana, Silvia Spinelli, Valentina Crippa, Elena Inzoli, Beatrice Manghisi, Ivan Civettini, Daniele Ramazzotti, Valentina Sangiorgio, Michele Gengotti, Virginia Brambilla, Andrea Aroldi, Federica Banfi, Cristiana Barone, Roberto Orsenigo, Ludovica Riera, Mara Riminucci, Alessandro Corsi, Massimo Breccia, Alessandro Morotti, Daniela Cilloni, Aldo M Roccaro, Antonio Sacco, Fabio Stagno, Marta Serafini, Federica Mottadelli, Giovanni Cazzaniga, Fabio Pagni, Roberto Chiarle, Emanuele Azzoni, Alessandro Sessa, Carlo B Gambacorti-Passerini, Elena Maria Elli, Luca Mologni, Rocco Giovanni Piazza
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood (2024)
Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, Rocco Piazza, Carlo Gambacorti-Passerini
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape. Annals of hematology 103 (5) (2024)
Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, Rocco Piazza, Carlo Gambacorti-Passerini
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape. Annals of hematology 103 (5) (2024)
Diletta Fontana, Federica Malighetti, Matteo Villa, Alfonso Zambon, Carlo B Gambacorti-Passerini, Luca Mologni
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. Leukemia (2024)
Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, Rocco Piazza, Carlo Gambacorti-Passerini
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape. Annals of hematology (2024)
Ilaria Crespiatico, Mattia Zaghi, Cristina Mastini, Deborah D'Aliberti, Mario Mauri, Carl Mirko Mercado, Diletta Fontana, Silvia Spinelli, Valentina Crippa, Elena Inzoli, Beatrice Manghisi, Ivan Civettini, Daniele Ramazzotti, Valentina Sangiorgio, Michele Gengotti, Virginia Brambilla, Andrea Aroldi, Federica Banfi, Cristiana Barone, Roberto Orsenigo, Ludovica Riera, Mara Riminucci, Alessandro Corsi, Massimo Breccia, Alessandro Morotti, Daniela Cilloni, Aldo M Roccaro, Antonio Sacco, Fabio Stagno, Marta Serafini, Federica Mottadelli, Giovanni Cazzaniga, Fabio Pagni, Roberto Chiarle, Emanuele Azzoni, Alessandro Sessa, Carlo B Gambacorti-Passerini, Elena Maria Elli, Luca Mologni, Rocco Giovanni Piazza
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood 143 (14) (2024)
Diletta Fontana, Federica Malighetti, Matteo Villa, Alfonso Zambon, Carlo B Gambacorti-Passerini, Luca Mologni
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1. Leukemia 38 (8) (2024)
Matteo Villa, Federica Malighetti, Elisa Sala, Geeta G Sharma, Giulia Arosio, Maria Gemelli, Chiara Manfroni, Diletta Fontana, Nicoletta Cordani, Raffaella Meneveri, Alfonso Zambon, Rocco Piazza, Fabio Pagni, Diego Luigi Cortinovis, Luca Mologni
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ precision oncology 8 (1) (2024)
Ilaria Crespiatico, Mattia Zaghi, Cristina Mastini, Deborah D'Aliberti, Mario Mauri, Carl Mirko Mercado, Diletta Fontana, Silvia Spinelli, Valentina Crippa, Elena Inzoli, Beatrice Manghisi, Ivan Civettini, Daniele Ramazzotti, Valentina Sangiorgio, Michele Gengotti, Virginia Brambilla, Andrea Aroldi, Federica Banfi, Cristiana Barone, Roberto Orsenigo, Ludovica Riera, Mara Riminucci, Alessandro Corsi, Massimo Breccia, Alessandro Morotti, Daniela Cilloni, Aldo M Roccaro, Antonio Sacco, Fabio Stagno, Marta Serafini, Federica Mottadelli, Giovanni Cazzaniga, Fabio Pagni, Roberto Chiarle, Emanuele Azzoni, Alessandro Sessa, Carlo B Gambacorti-Passerini, Elena Maria Elli, Luca Mologni, Rocco Giovanni Piazza
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. Blood (2024)
Diletta Fontana, Giovanni Paolo Maria Zambrotta, Antonio Scannella, Rocco Piazza, Carlo Gambacorti-Passerini
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape. Annals of hematology 103 (5) (2024)
Matteo Villa, Federica Malighetti, Elisa Sala, Geeta G Sharma, Giulia Arosio, Maria Gemelli, Chiara Manfroni, Diletta Fontana, Nicoletta Cordani, Raffaella Meneveri, Alfonso Zambon, Rocco Piazza, Fabio Pagni, Diego Luigi Cortinovis, Luca Mologni
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. NPJ precision oncology 8 (1) (2024)
Diletta Fontana, Elena Maria Elli, Fabio Pagni, Rocco Giovanni Piazza
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review. Cancers 15 (12) (2023)
Diletta Fontana, Ilaria Crespiatico, Valentina Crippa, Federica Malighetti, Matteo Villa, Fabrizio Angaroni, Luca De Sano, Andrea Aroldi, Marco Antoniotti, Giulio Caravagna, Rocco Giovanni Piazza, Alex Graudenzi, Luca Mologni, Daniele Ramazzotti
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients. Nature communications 14 (1) (2023)
Diletta Fontana, Elena Maria Elli, Fabio Pagni, Rocco Giovanni Piazza
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review. Cancers 15 (12) (2023)
Daniele Ramazzotti, Fabrizio Angaroni, Davide Maspero, Mario Mauri, Deborah D'Aliberti, Diletta Fontana, Marco Antoniotti, Elena Maria Elli, Alex Graudenzi, Rocco Piazza
Large-scale analysis of SARS-CoV-2 synonymous mutations reveals the adaptation to the human codon usage during the virus evolution. Virus evolution 8 (1) (2022)
Elisa Bossi, Andrea Aroldi, Lorenza Maria Borin, Luisa Verga, Diletta Fontana, Federica Cocito, Beatrice Manghisi, Giovanni Rindone, Fabrizio Cavalca, Alessia Ripamonti, Monica Raggi, Sergio Maria Ivano Malandrin, Annalisa Cavallero, Laura Antolini, Diego Bonardi, Rocco Giovanni Piazza, Carlo B Gambacorti-Passerini
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706). EJHaem (2022)
Carlo B Gambacorti-Passerini, Franck Emmanuel Nicolini, Richard A Larson, Andrea Aroldi, Diletta Fontana, Rocco Piazza, Philipp le Coutre, Laura Antolini, Sarit Assouline
Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. American journal of hematology 97 (8) (2022)
Giulia Arosio, Geeta Geeta Sharma, Matteo Villa, Mario Mauri, Ilaria Crespiatico, Diletta Fontana, Chiara Manfroni, Cristina Mastini, Marina Zappa, Vera Magistroni, Monica Ceccon, Sara Redaelli, Luca Massimino, Anna Garbin, Federica Lovisa, Lara Mussolin, Rocco Giovanni Piazza, Carlo Gambacorti-Passerini, Luca Mologni
Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. Cancers 13 (17) (2021)
Diletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza
Impact of ETNK1 somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage. Molecular & cellular oncology 8 (2) (2021)
Diletta Fontana, Mario Mauri, Rossella Renso, Mattia Docci, Ilaria Crespiatico, Lisa Marie Røst, Mi Jang, Antonio Niro, Deborah D'Aliberti, Luca Massimino, Mayla Bertagna, Giovanni Zambrotta, Mario Bossi, Stefania Citterio, Barbara Crescenzi, Francesca Fanelli, Valeria Cassina, Roberta Corti, Domenico Salerno, Luca Nardo, Clizia Chinello, Francesco Mantegazza, Cristina Mecucci, Fulvio Magni, Guido Cavaletti, Per Bruheim, Delphine Rea, Steen Larsen, Carlo B Gambacorti-Passerini, Rocco Giovanni Piazza
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. Nature communications 11 (1) (2020)
Elisa Bossi, Andrea Aroldi, Filippo A Brioschi, Carolina Steidl, Silvia Baretta, Rossella Renso, Luisa Verga, Diletta Fontana, Geeta Geeta Sharma, Luca Mologni, Lara Mussolin, Rocco Giovanni Piazza, Carlo B Gambacorti-Passerini
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. American journal of hematology 95 (12) (2020)